Artículos por temáticas

Levodopa and Plant-Derived Bioactive Compounds in Parkinson's Disease: Mechanisms, Efficacy, and Future Perspectives

Aktaş E, Hanağası HA, Özgentürk NÖ.

CNS Neurosci Ther. 2025 Aug;31(8):e70540. doi: 10.1111/cns.70540.

Intersection of Autonomic Dysfunction and Parkinson's Disease: Insights Into Neurogenic and Classical Orthostatic Hypotension

Pitton Rissardo J, Rashidi M, Rashidi F, Hmedat KI, Khalil I, Moharam H, Bahar M, Dway A, Prathiraja O, Fornari Caprara AL, Jayasinghe M.

Cureus. 2025 Jul 22;17(7):e88487. doi: 10.7759/cureus.88487. eCollection 2025 Jul.

Branched-Chain Amino Acids in Parkinson's Disease: Molecular Mechanisms and Therapeutic Potential

Huang HY, Tsao SP, Yeh TH.

Int J Mol Sci. 2025 Jul 21;26(14):6992. doi: 10.3390/ijms26146992.

The interrelationship between intestinal immune cells and enteric α-synuclein in the progression of Parkinson's disease

Cheng YK, Chiang HS.

Neurol Sci. 2025 Jul;46(7):2965-2977. doi: 10.1007/s10072-025-08114-w. Epub 2025 Mar 14.

Association between Parkinson's disease and risk of colorectal cancer: A systematic review and meta-analysis

Su MD, Wang TH, Zhang HW, Cao KY, Liu F.

Ibrain. 2025 Jan 22;11(2):205-214. doi: 10.1002/ibra.12193. eCollection 2025 Summer.

From postsynaptic neurons to astrocytes: the link between glutamate metabolism, Alzheimer's disease and Parkinson's disease

Liu FW, Zhang XR, Cong YF, Liu YM, Zhang HT, Hou XQ.

Rev Neurosci. 2025 Mar 20;36(6):689-700. doi: 10.1515/revneuro-2024-0143. Print 2025 Aug 26.

Efficacy and safety of GLP-1 agonists in Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials

Messak M, Abdelmageed A, Senbel AA, Khattab YA, Mandour Y, Shaker O, Rehan AH, Oransa S, Nasr M, Shabeeb AE, Rezq Z, Hossam F, Abouelmagd ME.

Naunyn Schmiedebergs Arch Pharmacol. 2025 Aug;398(8):9721-9736. doi: 10.1007/s00210-025-03932-3. Epub 2025 Mar 11.

Nanozymes in Parkinson's disease: strategic approaches, clinical considerations, and challenges

Huang W, Ye X, Huang Z, Li M, Yu B, Ye L, He S, Chen C.

J Mater Chem B. 2025 Jul 10;13(27):7919-7933. doi: 10.1039/d5tb00295h.

The Influence of Insulin Resistance and Type 2 Diabetes on Cognitive Decline and Dementia in Parkinson's Disease: A Systematic Review

Zeidan O, Jaragh N, Tama M, Alkhalifa M, Alqayem M, Butler AE.

Int J Mol Sci. 2025 Aug 21;26(16):8078. doi: 10.3390/ijms26168078.

Mitochondrial dysfunction and oxidative stress in Parkinson's disease: mechanisms, biomarkers, and therapeutic strategies

Usha Kiran P, Haria J, Rani R, Singh S.

Tissue Barriers. 2025 Aug 14:2537991. doi: 10.1080/21688370.2025.2537991. Online ahead of print.

Biological applications of graphene-based nanomaterials in neurodegenerative diseases

Zhu RK, Shi J, Zhou HJ, Ge L, Yin WH, Zeng H, Wang XW.

Mater Today Bio. 2025 Jul 9;33:102064. doi: 10.1016/j.mtbio.2025.102064. eCollection 2025 Aug.

Advancements in invasive and non-invasive neuromodulation for Parkinson's disease: current findings and future directions

Koirala N, Bange M, Wagle Shukla A, Muthuraman M.

NPJ Parkinsons Dis. 2025 Jul 30;11(1):221. doi: 10.1038/s41531-025-01071-3.

Effects of GBA1 Variants in Patients With Parkinson's Disease and Levodopa-Carbidopa Intestinal Gel: A Nation-Wide, Multicenter, Longitudinal, "Real-World" Study. The EPIC Study

Cilia R, Colucci F, Cereda E, Elia AE, Leta V, Barca S, Zibetti M, Carecchio M, Bonvegna S, Calandra-Buonaura G, Cerroni R, De Micco R, Tamburin S, Magistrelli L, Lena F, Mascia MM, Picillo M, Cossu G

Eur J Neurol. 2025 Jul;32(7):e70179. doi: 10.1111/ene.70179.

Neurodegeneration in Parkinson's disease: are we looking at the right spot?

Rocha GS, Freire MAM, Falcao D, Outeiro TF, Lima RR, Santos JR.

Mol Brain. 2025 Aug 1;18(1):68. doi: 10.1186/s13041-025-01218-6.

Carbon-based nanotechnology for Parkinson's disease: diagnostic and therapeutic innovations

Lafi Z, Asha S, Asha SY.

Nanomedicine (Lond). 2025 Aug;20(16):2023-2041. doi: 10.1080/17435889.2025.2535940. Epub 2025 Jul 23.